Texas Permanent School Fund Corp Grows Holdings in Lantheus Holdings, Inc. $LNTH

Texas Permanent School Fund Corp grew its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 12.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 88,298 shares of the medical equipment provider’s stock after purchasing an additional 9,801 shares during the quarter. Texas Permanent School Fund Corp owned approximately 0.13% of Lantheus worth $7,228,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in LNTH. Elevation Point Wealth Partners LLC purchased a new position in Lantheus in the 2nd quarter worth about $26,000. Osterweis Capital Management Inc. purchased a new stake in Lantheus in the 2nd quarter valued at about $36,000. Quarry LP grew its stake in Lantheus by 2,350.0% in the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock worth $48,000 after acquiring an additional 470 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Lantheus by 190.2% during the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock worth $87,000 after acquiring an additional 698 shares during the period. Finally, EMC Capital Management purchased a new position in shares of Lantheus during the second quarter worth approximately $93,000. 99.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on LNTH. B. Riley lowered their price target on Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a report on Tuesday, September 16th. Truist Financial set a $80.00 target price on Lantheus and gave the company a “buy” rating in a research report on Thursday, December 11th. The Goldman Sachs Group set a $77.00 target price on Lantheus and gave the stock a “neutral” rating in a report on Wednesday, October 8th. TD Cowen dropped their price target on Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, September 15th. Finally, Weiss Ratings lowered Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $77.33.

Lantheus Stock Performance

Shares of NASDAQ:LNTH opened at $65.17 on Wednesday. The firm has a 50 day moving average of $57.11 and a 200 day moving average of $62.88. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $4.32 billion, a price-to-earnings ratio of 27.38 and a beta of -0.10. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $92.51 million for the quarter. Lantheus had a return on equity of 30.88% and a net margin of 10.99%. On average, sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.